Immatics Announces Full Year 2023 Financial Results and Corporate Update
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objec…
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objec…
Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules Comp…
Clinical study demonstrates proof-of-concept for active personalized immunotherapy approach in a pioneering multi-center…
The prospect of an actively personalized approach to the treatment of glioblastoma has moved a step closer with the rece…
. - Regulatory authority approves clinical trial for Glioma Actively Personalized Vaccine Consortium (GAPVAC) - First…
. - Projekt wird gemeinsam von den Biotechnologiefirmen immatics (Tübingen) und BioNTech (Mainz) geleitet - Regulator…
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company leading the development of advanced immunother…
immatics biotechnologies GmbH, together with its collaborators Cancer Research UK and Cancer Research Technology today a…
immatics biotechnologies GmbH and Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced a strategic research and developmen…
. - immatics' lead cancer vaccine IMA901 to report interim phase 3 data in 2014 and final data in 2015 - Funding secur…